Afuco™ Anti-MS4A1 ADCC Therapeutic Antibody (Ocrelizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized antibody expressed in CHO binding to human MS4A1/CD20. Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets mature B lymphocytes and hence is an immunosuppressive drug candidate. It had reached Phase III clinical trials for rheumatoid arthritis and lupus erythematosus, and Phase II for multiple scleros is and hematological cancer.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-772 |
| Pricing | Inquiry |
| Host | Human |
| Target | MS4A1 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | ELISA, IP, FC, FuncS, Neut, IF |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |